Severe and reversible optic neuropathy by ethambutol and isoniazid

Authors

  • N. A. Rodríguez-Marco Complejo Hospitalario de Navarra A
  • S. Solanas-Álava
  • F.J. Ascaso
  • L. Martínez-Martínez
  • M.T. Rubio-Obanos
  • J. Andonegui-Navarro

DOI:

https://doi.org/10.23938/ASSN.0346

Keywords:

Visual field. Ethambutol. Isoniazid. Toxic optic neuropathy. Tuberculosis.

Abstract

Ethambutol and isoniazid are antimicrobial agents used to treat multi-drug-resistant tuberculosis. The most commonly recognized toxic effect of these drugs is optic neuropathy, usually manifesting as a decrease in visual acuity, deficits in colour vision and cecocentral scotomas.

This study presents the case of a 59-year-old Nigerian woman diagnosed of multi-drug-resistant tuberculosis who developed a severe bilateral optic neuropathy induced by ethambutol and isoniazid.

Ophthalmologic examination revealed normal intraocular pressure, normal funduscopic examination and normal biomicroscopy. Automated visual field revealed 360º peripheral constriction and central scotoma. Magnetic resonance images of the brain and orbits were normal. Ten months after suspending treatment, the patient recovered complete visual function.

Visual loss is a rare complication that can be related to ethambutol and isoniazid toxicity. Both eyes are usually symmetrically affected with deficits in colour vision and cecocentral scotoma. For successful treatment of visual loss, it is important to make a differential diagnosis between infection and adverse effects of anti-TB drugs. Ophthalmological examination is thus important before and after treatment.

Downloads

Download data is not yet available.

References

1. DE PALMA P, FRANCO F, BRAGLIANI G, MICHETTI L, MARESCOTTI A, PIRAZZOLI G et al. The incidence of optic neuropathy in 84 patients treated with ethambutol. Metab Pediatr Syst Ophthalmol 1989;12: 80-82.

2. BALAL M, PAYDAS S, SEYREK N, KARAYAYLALI I. Loss of vision and renal function in a patient with miliary tuberculosis. Mt Sinai J Med 2005; 72: 124-126.

3. KOCABAY G, ERELEL M, TUTKUN IT, ECDER T. Optic neuritis and bitemporalhemianopsia associated with isoniazid treatment in end-stage renal failure. Int J Tuberc Lung Dis 2006; 10: 1418-1419.

4. FURIA M, HAMARD H, GÉROLAMI I. Neuropathie optique toxique bilaterale a l'ethambutol et a l'isoniazide. Bull Soc Ophtalmol Fr 1986; 86: 1421-1422.

5. BOULANOUAR A, ABDALLAH E, EL BAKKALI M, BENCHRIFA F, BERRAHO-HAMANI A. Neuropathies optiques toxiques graves induites par l'isoniazide. A propos de trois cas. J Fr Ophtalmol 1995; 18:183-187.

6. CHAN RY, KWOK AK.Ocular toxicity of ethambutol. Hong Kong Med J 2006; 12: 56-60.

7. TALBERT ESTLIN KA, SADUN AA. Risk factors for ethambutol optic toxicity. Int Ophthalmol 2010; 30: 63-72.

https://doi.org/10.1007/s10792-009-9293-z

8. RAMOS MARTÍNEZ A, PORTERO GARCÍA JL, MURILLAS J, LOSADA I, MARTÍN H. Encefalopatía tóxica por isoniacida. Rev Neurol 1998; 26: 160.

https://doi.org/10.33588/rn.26149.981105

9. SHINDLER KS, ZURAKOWSKI D, DREYER EB. Caspase inhibitors block zinc-chelator induced death of retinal ganglion cells. Neuroreport 2000; 11: 2299-2302.

https://doi.org/10.1097/00001756-200007140-00046

10. HENG JE, VORWERCK CK, LESSELL E, ZURAKOWSKI D, LEVIN LA, DREYER EB. Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. Invest Ophthalmol Vis Sci 1999; 40: 190-196.

11. LAI TY, CHAN WM, LAM DS, LIM E. Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy. Br J Ophthalmol 2005; 89: 774-775.

https://doi.org/10.1136/bjo.2004.058099

12. KAHANA LM. Toxic ocular effects ofethambutol. CMAJ 1987; 137: 212-216.

13. STECHSCHULTE SU, KIM RY, CUNNINGHAM ET JR. Tuberculousneuroretinitis. J Neuroophthalmol 1999; 19: 201-204.

https://doi.org/10.1097/00041327-199909000-00009

14. MANSOUR AM. Optic disk tubercle. J Neuroophthalmol 1998; 18: 201-203.

https://doi.org/10.1097/00041327-199809000-00011

15. AKHADDAR A, EL HASSANI MY, CHAKIR N, JIDDANE M. Tuberculomeoptochiasmatique: complication d'une méningite tuberculeuse. À propos d'un cas et revue de la littérature. J Neuroradiol 2001; 28: 137-142.

16. LIM SA. Ethambutol-associated optic neuropathy. Ann Acad Med Singapore 2006; 35: 274-278.

https://doi.org/10.47102/annals-acadmedsg.V35N4p274

17. SIVAKUMARAN P, HARRISON AC, MARSCHNER J, MARTIN P. Ocular toxicity from ethambutol: a review of four cases and recommended precautions. N Z Med J 1998; 111: 428-430.

18. KUMAR A, SANDRAMOULI S, VERMA L, TEWARI HK, KHOSLA PK. Ocular ethambutol toxicity: is it reversible? J Clin Neuroophthalmol 1993; 13: 15-17.

19. TSAI RK, LEE YH. Reversibility of ethambutol optic neuropathy. J Ocul Pharmacol Ther 1997; 13: 473-477.

https://doi.org/10.1089/jop.1997.13.473

20. CHAI SJ, FOROOZAN R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol 2007; 91: 895-897.

https://doi.org/10.1136/bjo.2006.113118

Published

2014-09-05

How to Cite

1.
Rodríguez-Marco NA, Solanas-Álava S, Ascaso F, Martínez-Martínez L, Rubio-Obanos M, Andonegui-Navarro J. Severe and reversible optic neuropathy by ethambutol and isoniazid. An Sist Sanit Navar [Internet]. 2014 Sep. 5 [cited 2025 Dec. 15];37(2):287-91. Available from: https://recyt.fecyt.es/index.php/ASSN/article/view/22874

Issue

Section

Clinical notes

Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.